Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models.

17 Most importantly, we observed a highly significant increase in the survival of linsitinib-treated animals compared to vehicle controls (Figure 3 G).

also in 132,142 other papers

Likewise, IGF-1R inhibitor treatment lowered the mean platelet count, but this difference did not reach statistical significance (Figure 3 D).

also in 111,027 other papers